Company / PP&E (Net)
Fulgent Genetics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$112.5M
FY2025
5-year range
$62.3M / $112.5M
FY2021-FY2025
Trend
+6.6%
vs FY2024
Sector context
#81 of 130
Health Care
What the data says
At $113M, Fulgent Genetics, Inc.'s pp&e (net) ranks #81 of 130 in the Health Care sector. PP&E (Net) has increased for 6 consecutive years, from $6M in FY2019 to $113M in FY2025.
Based on SEC 10-K filings.
$113M in FY2025 with a 5-year CAGR of +22.9%.
Improved from $83M to $113M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +22.9%
- 10-Year CAGR
- -
Sector benchmark
#81 of 130 in Health CareTop 62% of 130This company $112.5M Sector average $1.3B
▼
-91.6% below sector average
Key checks
Key Insights
- Fulgent Genetics, Inc.'s pp&e (net) has grown for 6 consecutive years.
- 5-year CAGR of +22.9%, indicating consistent growth.
- In FY2025, pp&e (net) increased 6.6% year-over-year.
- Ranks #81 out of 130 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.5M | +6.6% |
| FY2024 | $105.5M | +26.5% |
| FY2023 | $83.5M | +2.6% |
| FY2022 | $81.4M | +30.6% |
| FY2021 | $62.3M | +54.9% |
| FY2020 | $40.2M | +572.9% |
| FY2019 | $6.0M | -7.3% |
| FY2018 | $6.4M | -11.4% |
| FY2017 | $7.3M | +16.7% |
| FY2016 | $6.2M | +152.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026